Latest News - Ocular Therapeutix

Monday, September 25, 2017 | Management/Leadership, Ocular Therapeutix

Ocular Therapeutix Appoints Donald Notman as Chief Financial Officer

Ocular Therapeutix announced the appointment of Donald Notman as Chief Financial Officer, effective immediately. Mr. Notman will replace interim CFO George Migausky and will be responsible for all str…

Read the full story

Monday, August 07, 2017 | Management/Leadership, Ocular Therapeutix

Ocular Therapeutix Appoints Daniel Bollag, PhD, as Senior Vice President, Regulatory Affairs, Pharmacovigilance and Quality

Ocular Therapeutiz announced the appointment of Daniel Bollag, PhD, as Senior Vice President, Regulatory Affairs, Pharmacovigilance and Quality, effective immediately. In his role, Mr. Bollag will be …

Read the full story

Wednesday, August 02, 2017 | Management/Leadership, Ocular Therapeutix

Ocular Therapeutix Announces Antony Mattessich Assumes Role as Chief Executive Officer

Ocular Therapeutix announced that in line with the company’s strategic plan and growth objectives announced in June, Antony Mattessich has assumed the role of Chief Executive Officer, effective …

Read the full story

Wednesday, July 12, 2017 | Miscellaneous, Ocular Therapeutix

FDA Rejects Ocular Therapeutix NDA for Dextenza for Second Time

Citing manufacturing concerns, Ocular Therapeutix failed for a second time to secure approval of Dextenza (dexamethasone insert) 0.4mg, which is being evaluated for the treatment of ocular pain follow…

Read the full story

Monday, July 10, 2017 | Miscellaneous, Ocular Therapeutix

Ocular Therapeutix Submits Amendment to Potentially Extend Review for Dextenza New Drug Application

Ocular Therapeutix announced that it has submitted details of a manufacturing equipment change as an amendment to the NDA resubmission for Dextenza (dexamethasone insert) 0.4 mg, for intracanalicular …

Read the full story

Friday, June 23, 2017 | Management/Leadership, Ocular Therapeutix

Ocular Therapeutix Announces Executive Transition Plans

Ocular Therapeutix announced that in line with Ocular’s strategic plan and growth objectives, Antony Mattessich will succeed Amar Sawhney, PhD, as Chief Executive Officer, on or before September…

Read the full story

Wednesday, May 10, 2017 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained-Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI)

Ocular Therapeutix presented data from preclinical studies evaluating the efficacy, tolerability, and pharmacokinetics of its sustained-release intravitreal tyrosine kinase inhibitor (TKI) depot (OTX-…

Read the full story

Monday, May 08, 2017 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Presents Additional Phase 3 Data and Patient Reported Outcomes Results for Dextenza at ASCRS

Ocular Therapeutix presented new data from its most recent phase 3 study evaluating the safety and efficacy of Dextenza (dexamethasone insert) 0.4 mg for the treatment of ocular pain and inflammation …

Read the full story

Monday, April 24, 2017 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix to Present Additional Phase 3 Data and Patient Reported Outcomes Results for Dextenza at ASCRS

Ocular Therapeutix announced new data to be presented from its most recent phase 3 study evaluating the efficacy and safety of Dextenza (dexamethasone insert, 0.4mg) for intracanalicular use for the t…

Read the full story

Wednesday, March 22, 2017 | Medical Studies, Ocular Therapeutix

New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ Dextenza Following Cataract Surgery

Ocular Therapeutix announced positive results of a patient experience study of Dextenza (dexamethasone insert) 0.4 mg for intracanalicular use. The study, published in Patient Preference and Adhe…

Read the full story

Wednesday, February 22, 2017 | Cataract Surgery, Ocular Therapeutix

Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for Dextenza for the Treatment of Ocular Pain After Ophthalmic Surgery

Ocular Therapeutix announced that the company’s new drug application (NDA) resubmission for Dextenza (dexamethasone insert) 0.4 mg for intracanalicular use for the treatment of ocular pain occur…

Read the full story

Monday, January 23, 2017 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Resubmits NDA for Dextenza for the Treatment of Ocular Pain After Ophthalmic Surgery

Ocular Therapeutix announced that it has resubmitted a new drug application (NDA) to the FDA for Dextenza (dexamethasone insert) 0.4 mg, for the treatment of ocular pain occurring after ophthalmic sur…

Read the full story

Wednesday, January 04, 2017 | Cataract Surgery, Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Announces Additional Successful Results for Phase 3 Clinical Trial of Dextenza

Ocular Therapeutix announced additional positive secondary endpoint results from its most recent successful phase 3 clinical trial of Dextenza (dexamethasone insert) 0.4 mg for the treatment of postsu…

Read the full story

Monday, November 14, 2016 | Clinical Trials, Ocular Therapeutix

Ocular Therapeutix Announces Successful Topline Results for Both Inflammation and Pain in Phase 3 Clinical Trial of Dextenza

Ocular Therapeutix announced positive topline results from its phase 3 clinical trial of Dextenza (dexamethasone insert) 0.4 mg for the treatment of postsurgical ocular inflammation and pain. Dextenza…

Read the full story

Friday, October 21, 2016 | Management/Leadership, Ocular Therapeutix

Ocular Therapeutix Appoints Andy Hurley Chief Commercial Officer

Ocular Therapeutix announced the appointment of Andy Hurley to the newly created position of chief commercial officer, effective immediately. In this role, Mr. Hurley will be responsible for leading O…

Read the full story
Load More